This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Doximity, Inc. Class A
Madison Square Garden Entertainment Corp.
LIQUIDIA TECHNOLOGIES INC
Alkermes Public Limited Company
Amphastar Pharmaceuticals Inc
Doximity, Inc. Class A DOCS | 0.00 | |
Madison Square Garden Entertainment Corp. MSGE | 0.00 | |
LIQUIDIA TECHNOLOGIES INC LQDA | 0.00 | |
Alkermes Public Limited Company ALKS | 0.00 | |
Amphastar Pharmaceuticals Inc AMPH | 0.00 |
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- B of A Securities analyst Allen Lutz downgraded Doximity Inc (NYSE:DOCS) from Buy to Underperform and cut the price target from $38 to $20. Doximity shares closed at $20.88 on Friday. See how other analysts view this stock.
- B of A Securities analyst Jason Gerberry downgraded Amphastar Pharmaceuticals, Inc (NASDAQ:AMPH) from Neutral to Underperform and lowered the price target from $25 to $20. Amphastar Pharma shares closed at $21.78 on Friday. See how other analysts view this stock.
- Seaport Global analyst David Joyce downgraded Madison Square Garden Entertainment Corp (NYSE:MSGE) from Buy to Neutral. Madison Square Garden shares closed at $80.30 on Friday. See how other analysts view this stock.
- B of A Securities analyst Jason Gerberry downgraded Liquidia Corp (NASDAQ:LQDA) from Buy to Neutral and raised the price target from $64 to $79. Liquidia shares closed at $78.17 on Friday. See how other analysts view this stock.
- B of A Securities analyst Jason Gerberry downgraded Alkermes Plc (NASDAQ:ALKS) from Neutral to Underperform and announced a $38 price target. Alkermes shares closed at $55.08 on Friday. See how other analysts view this stock.
Considering buying LQDA stock? Here’s what analysts think:
Photo via Shutterstock